Novartis submits meningitis B drug for US approval
ZURICH, June 17
ZURICH, June 17 (Reuters) - Swiss drugmaker Novartis said on Tuesday it had submitted its meningitis B vaccine Bexsero for adolescents and young people to the U.S. Food and Drug Administration (FDA) for marketing approval.
Bexsero, a broad coverage vaccine to help protect against meningitis B, is already approved in 34 countries including across the European Union, Canada and Australia, Novartis said.
Novartis has already provided nearly 30,000 doses of Bexsero to students and staff at Princeton University and the University of California Santa Barbara after meningitis B outbreaks on their campuses, the drugmaker said. (Reporting by Alice Baghdjian)
- Israel pummels Gaza; Kerry steps up diplomatic push |
- With sales sputtering, Apple's iPad looks to IBM alliance
- Ukraine war crimes trials a step closer after Red Cross assessment
- Five held in China food scandal probe, including head of Shanghai Husi Food
- Rebels likely downed Malaysian jet 'by mistake': U.S. officials